A multicenter, randomized, double-blind, comparison study of the safety and efficacy of a once-daily dose of tigecycline versus ertapenem for the treatment of foot infections in subjects with diabetes.

Trial Profile

A multicenter, randomized, double-blind, comparison study of the safety and efficacy of a once-daily dose of tigecycline versus ertapenem for the treatment of foot infections in subjects with diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ertapenem (Primary) ; Tigecycline (Primary)
  • Indications Bacterial infections; Diabetic foot ulcer; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 23 Jun 2012 Planned number of patients changed from 1061 to 1065 as reported by European Clinical Trials Database.
    • 25 Aug 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Planned number of patients changed from 781 to 1061 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top